RJNMSR
Review Journal of Neurological & Medical Sciences Review

Volume 4, Issue 3, 2026

THE DIGITAL TRANSFORMATION OF INFECTIOUS DISEASE MANAGEMENT: A COMPREHENSIVE ANALYSIS OF CLINICAL APPLICATIONS, REGULATORY EVOLUTION, AND GLOBAL HEALTH EQUITY: A NARRATIVE REVIEW

Noor Fatima[*1], Anum Syed[2], Aena Syed[3], Asma Mohsin[4], Mustafa Bashir Memon[5], Sidra Tar Muhammad[6], Alina Hamid[7]

[*1]*Department of Medicine, Dow Medical College, Karachi, Pakistan*
[2] *Department of Medicine, Dow International Medical College, Karachi, Pakistan*
[3,4,7] *Department of Medicine, Baqai Medical University, Karachi, Pakistan*
[5] *Medical Officer, District Health Office, Islamabad, Pakistan*
[6] *Medical Officer, Dow University of Health Sciences (OJHA CAMPUS), Karachi, Pakistan*

[1]drnoorfatima2000@gmail.com, [2]anumsyed3113@gmail.com, [3]aenasyed537@gmail.com, [4]mohsinasma399@gmail.com, [5]11mustafabashir11@gmail.com, [6]sidratahir292@gmail.com, [7]alinahamid245@gmail.com

Corresponding Author: *
Noor Fatima

DOI: http://doi.org/10.5281/zenodo.19247084

Received	Accepted	Published
18 January 2026	12 March 2026	27 March 2026

ABSTRACT

Introduction: *Digital technologies are fundamentally transforming infectious disease management across the continuum of care. Accelerated by the COVID-19 pandemic, tools such as artificial intelligence (AI), digital biomarkers, telemedicine, and digital adherence technologies (DATs) are reshaping how infections are diagnosed, treated, and monitored. However, realizing their full potential requires addressing challenges related to cybersecurity, regulatory harmonization, and global health equity.*

Methods: *A comprehensive analysis was conducted by reviewing current literature and evidence on digital health applications in infectious disease management from databases such as PubMed and Google Scholar. The review encompassed AI-driven diagnostics and drug discovery, wearable-based digital biomarkers, telemedicine platforms, DATs for tuberculosis (TB) and human immunodeficiency virus (HIV), evolving FDA/EMA regulatory frameworks, cybersecurity threats, and barriers to equitable implementation in low- and middle-income countries (LMICs). The search span takes around 3 months to study and identify the research gap across the present literature.*

Results: *AI-enhanced diagnostics demonstrated high accuracy in pathogen detection, including pneumonia identification via convolutional neural networks and accelerated tuberculosis screening. Generative AI frameworks expedited drug discovery through optimized Design-Make-Test cycles. Wearable devices detected pre-symptomatic viral infections using physiological parameters. Telemedicine consultations showed equivalence to in-person care, reducing mortality, hospital stays, and patient transfers. DATs improved TB treatment success (smartphone apps: OR 2.17; video-observed therapy: OR 4.69 for treatment completion). However, escalating ransomware attacks threaten patient safety,*

IoT device vulnerabilities persist, and significant digital divides remain with 0% versus 82% 5G coverage between low- and high-income countries.

Conclusion: *Digital medicine offers transformative potential for infectious disease management through personalized, timely interventions. Realizing equitable benefits requires sustained investment in cybersecurity infrastructure, harmonized regulatory frameworks, and deliberate strategies to bridge the digital divide, ensuring inclusive access across diverse populations globally.*

Keywords: *Artificial Intelligence; Digital Health; Wearable electronic devices; Infectious diseases; Tuberculosis; Hepatitis; Tele Medicine.*

INTRODUCTION

The landscape of clinical practice in infectious disease management is experiencing an unprecedented metamorphosis, characterized by the deep integration of digital technologies across the entire continuum of care. From the initial stages of pathogen identification and drug discovery to the longitudinal monitoring of patient recovery and the global surveillance of emerging outbreaks, digital medicine has emerged as a fundamental pillar of modern healthcare [Dong et al., 2025]. This paradigm shift, significantly accelerated by the exigencies of the COVID-19 pandemic, leverages artificial intelligence (AI), high-throughput sequencing (HTS), digital biomarkers, and remote monitoring to enable interventions that are not only timely but also increasingly personalized to the unique physiological and behavioral profile of the individual patient [Malhotra et al., 2025].

The integration of these technologies into clinical workflows is not merely a technical upgrade but a fundamental reconfiguration of how infectious diseases are diagnosed, treated, and managed. AI-driven diagnostics utilize machine learning and deep learning to parse vast datasets, identifying patterns in radiological images and genomic sequences that often elude human observation [Malhotra et al., 2025]. Simultaneously, digital biomarkers provide a continuous, real-world window into disease progression, offering objective measures of recovery and early warning signs of deterioration [Au et al., 2022]. Telemedicine platforms have bridged the gap between remote populations and specialized infectious disease expertise, ensuring that high-quality care is no longer a privilege of geographic proximity [amplifymd.com. *Accessed on february 28, 2026*].

However, the realization of this potential is contingent upon overcoming a series of systemic challenges. These include the maintenance of data integrity and privacy in an era of escalating cyber threats, the establishment of rigorous and harmonized regulatory frameworks to ensure the safety of digital therapeutics, and the urgent need to address the persistent inequities in access to these advanced technologies [van de Vijver et al., 2023]. The successful navigation of these barriers will define the future of global infectious disease preparedness and the ultimate efficacy of patient outcomes in the digital age.

Computational Intelligence and the Future of Pathogen Management

The application of artificial intelligence in infectious diseases represents a transition from traditional rule-based medicine to a data-driven paradigm. AI technology, by simulating core aspects of human cognition, enables the in-depth mining and precise interpretation of medical and microbiological data [Dong et al., 2025]. This provides clinicians and researchers with unprecedented perspectives and powerful analytical tools for accurate pathogen identification, the prediction of antibiotic resistance, and the assessment of epidemic trends [Dong et al., 2025].

Modern diagnostics in infectious diseases have moved beyond phenotypic screening toward AI-enhanced systems that improve both accuracy and efficiency [Malhotra et al., 2025]. Machine learning and deep learning algorithms are particularly effective in analyzing medical images, genetic information, and patient records to spot patterns missed by human practitioners. For example, convolutional neural networks have been deployed to analyze chest X-rays, identifying

pneumonia with exceptional accuracy. Similarly, AI-driven tools for analyzing sputum samples for tuberculosis have demonstrated the ability to operate much faster than traditional microscopy, facilitating earlier treatment and reducing the window for disease transmission [Malhotra et al., 2025]. Refer to **Table 1.**

Table 1: Artificial Intelligence in Diagnostics and Imaging

Diagnostic Modality	AI Integration Technique	Clinical Impact
Medical Imaging	Convolutional Neural Networks (CNN)	High-accuracy detection of pneumonia and TB
Pathogen Identification	High-Throughput Sequencing (HTS)	Real-time surveillance and early outbreak detection
Point-of-Care Testing	AI-enhanced Analysis	Improved accuracy for complex infections in resource-limited settings
Microbiological Data	Deep Learning (DL)	Precise interpretation of antibiotic resistance patterns

The clinical value of AI extends into the domain of predictive analytics, where algorithms sift through physiological, demographic, and historical data to propose personalized treatment strategies [Malhotra et al., 2025]. By integrating information from diverse sources, including electronic health records and environmental sensors, AI can forecast disease outbreaks and predict transmission patterns, which is critical for timely public health interventions [Malhotra et al., 2025].

Generative Design and AI in Drug Discovery

The development of novel therapeutics for infectious diseases is being revolutionized by AI-driven approaches that optimize every stage of the drug development lifecycle [Bon et al., 2025]. Traditional drug discovery often relies on phenotypic screening or target-based design, both of which are resource-intensive and prone to high failure rates. AI frameworks, such as GAMBIT and REINVENT, utilize generative design to create molecules that match specific desired pharmacophores [Bon et al., 2025]. This is particularly valuable when anti-infective drug targets are well-defined structurally, allowing for 3D Hybridization with novel chemical matter to target conserved residues that are less prone to mutations.

The Design-Make-Test (DMT) cycle is further accelerated through active learning [Bon et al., 2025]. In this iterative process, a small set of labelled molecules is used to train an initial predictive model. The model then identifies the most "uncertain" molecules from a larger, unlabelled dataset those it considers the most valuable for learning which are then synthesized and tested [Bon et al., 2025]. The results are fed back into the model, improving its ability to identify promising candidates in subsequent iterations. To ensure the speed of this learning process, automated synthesis and testing are paramount, with AI algorithms predicting synthesis pathways that are compatible with automation [Bon et al., 2025].

In the realm of antifungal drug development, where the need for novel agents is urgent due to rising resistance, AI has facilitated the identification of antimicrobial peptides like AMP-29, which has shown efficacy against Candida Glabarata in murine models [Li et al., 2025]. By leveraging machine learning classifiers, researchers can rank drug resistance mutations, providing a cost-effective method for monitoring evolving fungal threats [Li et al., 2025].

AI is fundamentally altering the traditionally long and resource-intensive vaccine development process. By analyzing massive amounts of biological data, AI systems can identify potential antigens and predict their effectiveness in triggering an immune response [Malhotra et al., 2025]. Tools like nHLAPred and MHC2Pred utilize artificial neural networks to pinpoint epitopes capable of binding to MHC class I alleles, significantly narrowing the list of candidates for experimental validation [Malhotra et al., 2025]. This data-driven approach allows for rapid responses to emerging infectious threats, as demonstrated during the global efforts to develop vaccines for COVID-19. The optimization of clinical trials is another critical application. AI can assist in the selection of trial participants who are most likely to provide clear evidence of a vaccine's efficacy and can forecast potential adverse reactions early in the process [Malhotra et al., 2025]. This enhances both the safety and the efficiency of the trial, increasing the likelihood of regulatory approval and successful deployment. Refer to **Table 2.**

Table 2: Antigen Discovery and Vaccine Development

Vaccine Development Phase	AI Application	Core Mechanism
Antigen Discovery	Epitope Prediction	Analyzing biological data to identify immune-triggering antigens
Allele Binding	nHLAPred / MHC2Pred	Forecasting peptide binders for MHC class I and II
Trial Optimization	Predictive Modelling	Selecting suitable candidates and forecasting side effects
Response Monitoring	Data-Driven Feedback	Evaluating vaccine effectiveness across diverse populations

Digital Biomarkers and the Evolution of Remote Monitoring

Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected and measured by means of digital devices such as portables, wearables, implantable, or digestible [Au et al., 2022]. In infectious disease management, these biomarkers offer a path toward continuous, real-time health tracking and illness prediction in free-living and remote conditions [Goergen et al., 2022]. They provide a longitudinal perspective on a patient's health that is often missing from traditional, single-point-in-time clinical measurements [Goergen et al., 2022]. Advancements in wearable sensors have enabled the continuous collection of raw physiological parameters, including heart rate, heart rate variability (HRV), respiratory rate, blood pressure, oxygen saturation, and skin temperature [Goergen et al., 2022]. Clinical evidence suggests that viral infections lead to detectable changes in these metrics such as an increase in resting heart rate or a decrease in HRV well before the onset of symptoms [Goergen et al., 2022]. For example, research using data from wrist-worn devices like Fitbit demonstrated the ability to identify COVID-19 infection based on four days of prior physiological data, often identifying asymptomatic or pre-symptomatic cases [Ni et al., 2021]. Beyond cardiorespiratory metrics, novel biomarkers like mechanoacoustic signatures are gaining prominence. Soft, skin-mounted electronics can now track cough frequency and intensity with high fidelity, providing a quantitative basis for monitoring the progression of respiratory infections and the patient's response to therapeutics [Ni et al., 2021]. Furthermore, vocal biomarkers are being explored for their potential

to diagnose and monitor conditions like long COVID, where respiratory insufficiency can lead to subtle but detectable changes in vocal phonation and airflow [Fischer et al., 2022]. Refer to **Table 3.**

Table 3: Biometric Monitoring Technologies (BioMeTs)

Form Factor	Primary Parameters Tracked	Clinical Use Case
Smartwatches / Wristbands	HR, HRV, RR, Activity, Sleep	Early viral infection detection and general wellness [3]
Smart Rings	Temperature, HRV, Sleep	Continuous monitoring for prodromal infection signs [3]
Skin-Mounted Patches	Mechanoacoustic (MA) signatures	Cough frequency and intensity, core vitals [6]
Smart Clothing	Posture, Movement, RR	Long-term recovery monitoring for respiratory illness [3]

Early Warning Systems for Sepsis

Sepsis is a critical area where digital biomarkers and predictive modelling can have a life-saving impact. Because sepsis can progress with lethal speed, early detection is essential. Predictive algorithms, such as the Epic Sepsis Model, analyze multiparametric vital signs including heart rate, respiratory rate, and blood pressure alongside laboratory data to recognize patterns of clinical decompensation [Goergen et al., 2022]. While some existing models have faced criticism regarding their positive predictive value in real-world settings, the integration of multi-omics data (genomics, proteomics, and metabolomics) is expected to significantly refine these systems [Goergen et al., 2022].

The future of sepsis care involves a shift from reactive to proactive management. By integrating information from multiple biomarkers and using machine learning to identify complex, nonlinear relationships in heterogeneous clinical data, physicians can more accurately predict a patient's disease course [Jin et al., 2025]. This facilitates the goal of personalized medicine, providing tailored prevention and treatment measures that are integrated directly into the clinical workflow [Jin et al., 2025].

Characterizing Long COVID and Post-Acute Syndromes

The persistent and often varied symptoms of Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 (PASC), present a significant challenge for traditional diagnostic models. Researchers in the RECOVER adult cohort have utilized digital data and clinical laboratory values to develop a research index that helps classify symptomatic Long COVID into distinct subtypes [recovercovid.org. *Accessed on February 28, 2026*]. As of 2024, the index identified five symptom clusters, reflecting the diverse ways in which the condition can manifest across multiple body systems [recovercovid.org. *Accessed on february 28, 2026*].

The use of digital phenotyping capturing passive data like movement patterns and sleep metrics alongside active assessments like cognitive tests allows for the objective monitoring of symptoms such as fatigue [Rudroff 2025]. This is particularly important because Long COVID symptoms can be subjective and vary greatly between cases. Establishing digital biomarkers for fatigue and other PASC symptoms can enable the development of early warning systems and more effective interventions [recovercovid.org. *Accessed on february 28, 2026*].

Telemedicine and the Virtualization of Specialist Care

Telemedicine has emerged as a cornerstone of infectious disease management, particularly in addressing the geographic maldistribution of specialist expertise. Infectious disease (ID) specialists are predominantly located in large academic medical canters, leaving up to 45% of hospitals in the United States without on-site ID expertise [Burnham et al., 2019]. Telemedicine effectively bridges this gap, allowing specialists to provide high-quality consultations to underserved and rural areas [amplifymd.com. *Accessed on february 28, 2026*].

Tele-ID consultations involve the remote assessment of laboratory results, cultures, imaging, and patient history to manage even the most complex cases [amplifymd.com. *Accessed on february 28, 2026*]. Studies have demonstrated that these virtual consultations are equivalent to in-person visits in terms of quality of care and can lead to improved clinical outcomes, such as a reduction in 30-day mortality and a decrease in the length of hospital stays. Furthermore, telemedicine can significantly reduce the need for patient transfers to larger facilities, lowering costs for both hospitals and families and allowing local systems to maintain patient care within their communities [amplifymd.com. *Accessed on february 28, 2026*]. Beyond direct patient care, telemedicine facilitates continuing medical education for providers in remote areas, ensuring that the latest clinical guidelines and treatment strategies are disseminated effectively across the healthcare network [Palacholla et al., 2019]. This collaborative model, where remote specialists support bedside healthcare providers, is a win-win for both patients and hospitals, enhancing antibiotic stewardship and infection control [amplifymd.com. *Accessed on february 28, 2026*]. Refer to **Table 4.**

Table 4: Bridging the Access Gap and Improving Outcomes

Telemedicine Outcome	Measured Impact	Evidence Basis
Clinical Quality	Equivalent to in-person consultations	Multiple studies in HIV, HCV, and TB
Hospital Stay	Decrease in length of stay	Eron et al. and Assimacopoulos et al.
Treatment Initiation	Faster response times for antibiotics	Tele-ID specialists often provide 24/7 coverage
Patient Transfers	Reduction in facility-to-facility transfers	Increased local hospital capability and patient satisfaction

Workflow Adaptations and Inpatient Implementation

The rapid deployment of inpatient telemedicine as an infection control strategy during the pandemic highlighted both the flexibility of the technology and the challenges of its integration into clinical workflows. Inpatient telemedicine was found to be effective in reducing staff exposure to infectious agents and conserving personal protective equipment (PPE) [Safaeinili et al., 2021]. However, the burden of this implementation was often unevenly distributed among clinical team members.

While physician workflows remained relatively stable, as most standard clinical activities could be conducted via video after an initial physical exam, nursing workflows required significant adaptation [Safaeinili et al., 2021]. Nurses often took on non-nursing duties, such as facilitating technology connections for both patients and physicians, while bearing a higher burden of in-person care. Additionally, some resident physicians reported a

reduction in educational opportunities, as the shift to virtual encounters limited their ability to conduct physical examinations [Safaeinili et al., 2021]. Successful long-term integration of these technologies requires addressing these operational burdens through improved technical support, training, and remote access functionality [Safaeinili et al., 2021]. Incomplete adherence to medication is a major driver of treatment failure, relapse, and the development of antimicrobial resistance, particularly in conditions like tuberculosis (TB) and HIV [Mohamed et al., 2025]. Digital adherence technologies (DATs) offer a more person-centric approach to supporting patients through long-term treatment regimens, often replacing or augmenting more intrusive traditional methods like directly observed therapy (DOT) [Mohamed et al., 2025]. Refer to **Table 5.**

Table 5: Digital Adherence Technologies and Treatment Success

DAT Intervention Type	Target Condition	Key Efficacy Metric
Video-Observed Therapy (VOT)	TB Infection	OR 4.69 for treatment completion
Smartphone Applications	TB Disease	OR 2.17 for treatment success in RCTs
SMS Systems (WelTel)	HIV Care	Increased rates of viral suppression
Medication Sleeves (99DOTS)	TB Disease	Generally preferred but modest impact on short-term clinical outcomes
Smart Pillboxes / Dispensers	Chronic Diseases	Improved adherence by 10-34% across studies

Evidence-Based Impact in Tuberculosis Care

DATs for TB include SMS-based reminders, medication sleeves with phone-call verification (such as 99DOTS), digital pillboxes, and video-observed therapy (VOT) [Mohamed et al., 2025]. A systematic review and meta-analysis of 76 studies indicated that the use of DATs is associated with a modest increase in treatment success for TB disease, with smartphone apps showing a significant positive effect in randomized controlled trials (OR 2.17) [Mohamed et al., 2025].

VOT, which allows healthcare providers to remotely verify medication adherence through video, has proven particularly effective for patients with TB infection, significantly increasing the likelihood of treatment completion (OR 4.69) [Meghashree et al., 2025]. While DATs do not always improve every clinical outcome, they are often preferred by patients over traditional DOT due to their lower level of intrusiveness and higher convenience. Furthermore, DAT use has been linked to a significant increase in the reporting of adverse events, allowing clinicians to address side effects more promptly [Mohamed et al., 2025].

HIV Management and the Role of Persistence

In HIV care, digital tools like the WelTel SMS-based system have been shown to improve medication adherence and increase rates of viral suppression [Mohamed et al., 2025]. The public health impact of non-adherence in HIV is profound, as it not only affects individual health but also results in ongoing transmission of the

virus [Annabel 2026]. Recent studies, such as the LATITUDE study, have explored the use of long-acting injectable antiretroviral therapies for individuals who have historically struggled with daily oral medication adherence [Annabel 2026]. The study found that injectable regimens were significantly more effective in preventing regimen failure, with a failure rate of 22.8% compared to 41.2% in the oral ART group [Annabel 2026].

Managing non-adherence requires a nuanced understanding of the patient's perspective. Research suggests that a significant proportion of "unintentional" mistakes, such as running out of pills or missing a dose, often have roots in intentional behaviors or socio-economic challenges [Aadia 2026]. Digital tools that combine reminders with active support, AI messaging, and caregiver involvement are the most effective in maintaining long-term engagement [Aadia 2026].

The rapid advancement of digital medicine necessitates robust regulatory and governance frameworks to ensure that these technologies are safe, effective, and ethically sound. Regulatory bodies like the FDA and EMA are increasingly collaborating to establish guidelines that balance innovation with patient protection. Refer to **Table 6.**

Table 6: Regulatory and Governance Frameworks for Digital Health

Regulatory Concept	Definition	Regulatory Agency Basis
Fit-for-Purpose	Validation level supporting DHT measure interpretation for proposed use	FDA / Modern Validity Theory
Context of Use (COU)	The specific clinical condition and trial environment for the DHT	FDA / EMA Human Medicines Division
Clinical Outcome Assessment	DHT measure treated as a formal assessment of patient status	FDA Series of Guidance (34-37)
Qualification	General application of a methodology to support drug approval	EMA Human Medicines Division

Collaborative AI Principles for Drug Development

In January 2026, the FDA and EMA released a joint guidance framework for the use of AI in drug development, highlighting ten key principles for good practice [Hill et al., 2025]. The agencies emphasize that AI technologies should be high-quality, human-centric, and compliant with tightening ethical, legal, scientific, regulatory, and cybersecurity standards [Hill et al., 2025]. Crucially, drug developers are encouraged to keep detailed and traceable records on data sources and processing steps to remain in line with Good Practice (GxP) requirements [Hill et al., 2025].

Data used to train AI models must be "fit-for-use," and models themselves must undergo regular, risk-based performance assessments throughout their entire lifecycle [Hill et al., 2025]. This includes investigating human-AI interactions to ensure that the information presented to end-users is digestible and relevant [Hill et al., 2025].

Qualification of Digital Health Technologies (DHTs)

The regulatory acceptance of digital health technologies for use in clinical trials is a multifaceted process. Regulators require evidence that a DHT-derived measure is relevant to a

"meaningful aspect of health" for the patient [Anita 2026]. This is often referred to as being "fit for purpose" within a specific Context of Use (COU) [Anita 2026]. For example, if an accelerometer is used to track activity in a clinical trial for a respiratory infection, the sponsor must show that the metrics derived such as step count or vigorous activity can be linked to the concept of interest for that specific condition [Anita 2026]. Agencies like the FDA have established specialized committees, such as the DHT Steering Committee and the Digital Health Center of Excellence, to provide scientific expertise and connect stakeholders in the digital health space [Thomasian and Adashi 2021]. The trend toward the acceptance of digital endpoints is growing, with the EMA recently accepting stride velocity as a primary endpoint in certain studies, signaling a broader openness to digital measures in drug approval processes [Thomasian and Adashi 2021]. As clinical practice becomes increasingly digitized, the risks associated with cybersecurity have escalated from technical concerns to critical patient safety issues [Bakheet 2025]. The reliance on interconnected systems, electronic health records (EHRs), and remote monitoring devices has opened new avenues for malicious actors to exploit [Bakheet 2025]. Refer to **Table 7.**

Table 7: Cybersecurity Challenges in the Digital Health Landscape

Cybersecurity Challenge	Specific Vulnerability	Mitigation Strategy
Endpoint Complexity	Unpatched patient-monitoring and IoT devices	Robust device management and automated patching
Remote Work Risks	VPN and RDP vulnerabilities used by staff	Multi-factor authentication, firewalls, and whitelisting
Human Error	Phishing and social engineering targeting stressed staff	Continuous security training and culture of hygiene
Third-Party Reliance	Critical healthcare service providers (Change HC)	Business continuity planning and multi-vendor strategies
Data Integrity	Siloed EHR systems and lack of architecture	Coherent, interoperable data infrastructure

The Rising Threat of Ransomware and Third-Party Attacks

The healthcare sector has seen a staggering increase in the frequency and complexity of cyberattacks. Phishing and computer viruses are the most common vectors, but ransomware poses the most significant threat to clinical operations [Bakheet 2025]. The 2024 attack on United Health Group's subsidiary Change Healthcare was the most consequential in U.S. history, impacting virtually every hospital by disrupting critical functions like claims processing and clinical criteria management [He et al., 2021].

Ransomware attacks are increasingly sophisticated, with Iranian-based actors sometimes collaborating with Russian-affiliated groups to facilitate ESP espionage and profit-driven attacks [He et al., 2021]. These incidents highlight the vulnerability of the healthcare supply chain and the need for organizations to prepare for the extended loss of

services caused by third-party breaches [He et al., 2021].

Vulnerabilities in IoT and Connected Medical Devices

The proliferation of Internet of Things (IoT) medical devices has introduced thousands of new entry points for cybercriminals. Many of these devices, which comprise patient-monitoring equipment and critical care systems in the ICU, are often unpatched or integrated with outdated legacy systems, making them highly vulnerable [Bakheet 2025]. The manipulation of interconnected medical devices, such as anesthesia or ventilation systems, presents a direct threat to patient life, potentially leading to altered treatment plans or erroneous data that misguides clinical intervention [Bakheet 2025].

Addressing these challenges requires a shift in perspective. Cybersecurity must be viewed as a patient safety imperative rather than just an IT department concern [John 2024]. This involves a proactive approach that prioritizes up-to-date technologies, rigorous training for healthcare staff, and the implementation of high-impact Cybersecurity Performance Goals (CPGs) as recommended by health and human services departments [Bakheet 2025; Amir et al., 2025]. The promise of digital medicine is often hindered by a persistent digital divide, where the populations that most need timely and accurate health information are excluded due to a lack of infrastructure, digital literacy, and economic resources [Yao et al., 2022]. This is particularly evident in low- and middle-income countries (LMICs). Refer to **Table 8.**

Table 8: Bridging the Digital Divide: Equity in Access and Implementation

Equity Barrier	Impact on LMIC Population	Mitigation / Practical Strategy
Infrastructure	0% vs 82% 5G coverage (low- vs high-income)	Satellite and mobile internet expansion
Digital Literacy	12% vs 41% median proficiency	Community-based training for apps and portals
Financial Barrier	Device and data costs are prohibitive	Subsidized/loaner devices and PPPs
Language/Culture	37% of patients feel language is a barrier	Multilingual and culturally adapted interfaces
Systemic Inequity	Fragmented, donor-driven initiatives	Alignment with national health strategies

Barriers to Implementation in LMICs

In many LMICs, digital health initiatives remain fragmented, poorly coordinated, and underfunded [de Andrade et al., 2026]. Infrastructure deficiencies are a major hurdle, including poor internet connectivity, limited or unreliable power supplies, and a lack of secure data storage [van de Vijver et al., 2023]. Furthermore, many of these countries face a significant workforce shortage, which is expected to hit LMICs hardest by 2030 [van de Vijver et al., 2023].

Financial constraints are acute; the annual health expenditure per capita in Africa is less than one-tenth of the global average, and many nations have not met budgetary pledges for health, such as the Abuja Declaration goal of 15% of national budgets [de Andrade et al., 2026]. This leads to a reliance on private development partners, which can result in the "verticalization" of services investments determined by the specific interests of donors rather than national healthcare priorities [de Andrade et al., 2026].

Intervention Generated Inequalities and Health Equity

There is a significant risk that the rapid adoption of digital technologies will widen existing health inequities. Digital health solutions tend to work better for those who are already socio-economically better off, a situation referred to as Intervention-Generated Inequalities [Nanyonga et al., 2026]. COVID-19 impact and factors such as age, region, and literacy level can influence an individual's ability to obtain and adopt technology, leading to different disease outcomes among different populations [Nanyonga et al., 2026]. To overcome these barriers, digital health investments must be embedded in robust governance frameworks and supported by long-term financing that balances public, private, and donor contributions [de Andrade et al., 2026]. Bridging the divide requires more than just deploying technology; it demands infrastructure investment, digital literacy education, and community partnerships that prioritize equity and local context [Yao et al., 2022].

Conclusion

The transition to digital medicine in infectious disease management is a transformative process that offers profound opportunities to improve patient care and global health security. The integration of AI-driven diagnostics, digital biomarkers, and remote monitoring has provided clinicians with a powerful toolkit for the early detection and personalized treatment of infections. Telemedicine has redefined the boundaries of specialist care, ensuring that expertise can reach the most remote populations. Digital adherence technologies are offering new pathways for the successful management of chronic infections like TB and HIV, prioritizing the patient's experience and autonomy.

However, the full realization of these benefits is not guaranteed. It requires a sustained commitment to addressing the systemic challenges of cybersecurity, data integrity, and regulatory harmonization. Most importantly, it demands a concerted effort to close the digital divide and ensure that the fruits of innovation are shared equitably across the globe. By aligning technological advancement with robust governance and a focus on health equity, the healthcare community can build a more resilient and effective system for managing infectious diseases in the 21st century and beyond. The future of infectious disease care is not just digital; it is integrated, data-driven, and, ideally, inclusive.

Author Contributions

All authors equally contributed to the study and approved the final manuscript.

REFERENCES

Dong C, Liu Y, Nie J, Zhang X, Yu F, Zhou Y. Artificial Intelligence in Infectious Disease Diagnostic Technologies. Diagnostics. 2025 Oct 15;15(20):2602. https://doi.org/10.3390/diagnostics15202602

Malhotra Y, Yadav D, Chaturvedi N, Gujar A, John R, Ahmad K. AI in infectious disease diagnosis and vaccine development. InMethods in Microbiology 2025 Jan 1 (Vol. 56, pp. 191-218). Academic Press. https://doi.org/10.1016/bs.mim.2024.12.005

Au R, Kolachalama VB, Paschalidis IC. Redefining and validating digital biomarkers as fluid, dynamic multi-dimensional digital signal patterns. Frontiers in Digital Health. 2022 Jan 13;3:751629. https://doi.org/10.3389/fdgth.2021.751629

Tele Infectious Disease Specialists Improve Quality Outcomes - AmplifyMD, accessed on February 28, 2026. Available from: https://amplifymd.com/tele-infectious-disease-specialists-improve-quality-outcomes/

van de Vijver S, Tensen P, Asiki G, Requena-Méndez A, Heidenrijk M, Stronks K, Cobelens F, Bont J, Agyemang C. Digital health for all: how digital health could reduce inequality and increase universal health coverage. Digital health. 2023 Jul;9:20552076231185434. https://doi.org/10.1177/20552076231185434

Bon M, Cunningham F, Chauhan J, Lu B, Jain S, Probst B, Goodfellow I, Bresciani A. AI Drug Discovery: Expanding the Horizons of Infectious Disease Therapeutics. ACS Infectious Diseases. 2025 Jul 16;11(8):2048-50. https://doi.org/10.1021/acsinfecdis.5c00462

Li Y, Qiao Y, Ma Y, Xue P, Ding C. AI in fungal drug development: opportunities, challenges, and future outlook. Frontiers in cellular and infection microbiology. 2025 May 21;15:1610743. https://doi.org/10.3389/fcimb.2025.1610743

Goergen CJ, Tweardy MJ, Steinhubl SR, Wegerich SW, Singh K, Mieloszyk RJ, Dunn J. Detection and monitoring of viral infections via wearable devices and biometric data. Annual review of biomedical engineering. 2022 Jun 6;24(1):1-27.

Ni X, Ouyang W, Jeong H, Kim JT, Tzavelis A, Mirzazadeh A, Wu C, Lee JY, Keller M, Mummidisetty CK, Patel M. Automated, multiparametric monitoring of respiratory biomarkers and vital signs in clinical and home settings for COVID-19 patients. Proceedings of the National Academy of Sciences. 2021 May 11;118(19):e2026610118. https://doi.org/10.1073/pnas.2026610118

Fischer A, Elbeji A, Aguayo G, Fagherazzi G. Recommendations for successful implementation of the use of vocal biomarkers for remote monitoring of COVID-19 and long COVID in clinical practice and research. Interactive Journal of Medical Research. 2022 Nov 15;11(2):e40655. https://doi.org/10.2196/40655

Jin X, Shen H, Zhou P, Yang J, Yang S, Ni H, Yu Y, Zhang Z. Research Progress on Sepsis Diagnosis and Monitoring Based on Omics Technologies: A Review. Diagnostics. 2025 Nov 14;15(22):2887. https://doi.org/10.3390/diagnostics15222887

R3 Seminar Recap: Characterization of PASC and investigation of biomarkers: Insights from the RECOVER adult cohort, accessed on February 28, 2026. Available from: https://recovercovid.org/r3-seminar-series/characterization-pasc-and-investigation-biomarkers-insights-recover-adult-cohort

Rudroff T. Digital biomarkers and AI for remote monitoring of fatigue progression in neurological disorders: bridging mechanisms to clinical applications. Brain Sciences. 2025 May 21;15(5):533. https://doi.org/10.3390/brainsci15050533

Burnham JP, Fritz SA, Yaeger LH, Colditz GA. Telemedicine infectious diseases consultations and clinical outcomes: a systematic review. InOpen forum infectious diseases 2019 Dec (Vol. 6, No. 12, p. ofz517). US: Oxford University Press. https://doi.org/10.1093/ofid/ofz517

Palacholla RS, Kvedar JC. Telemedicine for infectious disease care—how do we measure the true value?. Annals of Translational Medicine. 2019 Sep;7(Suppl 6):S178. https://doi.org/10.21037/atm.2019.07.81

Safaeinili N, Vilendrer S, Williamson E, Zhao Z, Brown-Johnson C, Asch SM, Shieh L. Inpatient telemedicine implementation as an infection control response to COVID-19: qualitative process evaluation study. JMIR Formative Research. 2021 Jun 16;5(6):e26452. https://doi.org/10.2196/26452

Mohamed MS, Zary M, Kafie C, Chilala CI, Bahukudumbi S, Foster N, Gore G, Fielding K, Subbaraman R, Schwartzman K. The impact of digital adherence technologies on treatment outcomes, adherence, and patient-reported outcomes in tuberculosis: a systematic review and meta-analysis. BMC Infectious Diseases. 2025 Oct 14;25(1):1314. https://doi.org/10.1186/s12879-025-11503-3

Meghashree N, Kushal C B, Shivaraj D R, A Review on Digital Adherence Technologies for Chronic Disease Management: Global Evidence, Implementation Gaps, and Future Directions, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 9, 787-806. https://doi.org/10.5281/zenodo.17068024

Annabel Kartal Allen. FDA and EMA release collaborative AI framework for drug ..., accessed on February 28, 2026. Available from: https://www.clinicaltrialsarena.com/news/fda-ema-ai-guidance-pharma-drug-development/?cf-view

Aadia Rana. UAB leads study to mitigate the medication adherence barriers in those living with HIV, accessed on February 28, 2026. Available from: https://www.uab.edu/news/research-innovation/uab-leads-study-to-mitigate-the-medication-adherence-barriers-in-those-living-with-hiv

Hill DL, Carroll C, Belfiore-Oshan R, Stephenson D. Aligning with regulatory agencies for the use of digital health technologies in drug development: a case study from Parkinson's disease. Frontiers in digital health. 2025 Oct 23;7:1415202. https://doi.org/10.3389/fdgth.2025.1415202

Anita Burrell. Where The FDA And EMA Stand On Digital Endpoints - Clinical Leader, accessed on February 28, 2026. Available from: https://www.clinicalleader.com/doc/where-the-fda-and-ema-stand-on-digital-endpoints-0001

Thomasian NM, Adashi EY. Cybersecurity in the internet of medical things. Health Policy and Technology. 2021 Sep 1;10(3):100549. https://doi.org/10.1016/j.hlpt.2021.100549

Bakheet A. Cybersecurity in Healthcare: New Threat to Patient Safety. Cureus. 2025;17(5). https://doi.org/10.7759/cureus.83614

He Y, Aliyu A, Evans M, Luo C. Health care cybersecurity challenges and solutions under the climate of COVID-19: scoping review. Journal of medical Internet research. 2021 Apr 20;23(4):e21747. https://doi.org/10.2196/21747

John Riggi. A Look at 2024's Health Care Cybersecurity Challenges | AHA News, accessed on February 28, 2026. Available from: https://www.aha.org/news/aha-cyber-intel/2024-10-07-look-2024s-health-care-cybersecurity-challenges

Amir AS, Mulyana D, Dida S, Suminar JR. Bridging the digital divide: Enhancing doctor-patient communication through digital media platforms. Journal of Education and Health Promotion. 2025 Oct 1;14(1):423. https://doi.org/10.4103/jehp.jehp_1215_24

Yao R, Zhang W, Evans R, Cao G, Rui T, Shen L. Inequities in health care services caused by the adoption of digital health technologies: scoping review. Journal of medical Internet research. 2022 Mar 21;24(3):e34144. https://doi.org/10.2196/34144

de Andrade JB, Fagundes TP, Katsuyama E, Silva GS. Digital health in low-resource settings: Comprehensive challenges and opportunities with a focus on stroke care. Stroke. 2026 Jan;57(1):245-53. https://doi.org/10.1161/strokeaha.125.050448

Nanyonga S, Crevola LM, Blanshard P, Simeon-Dubach D. Digitalisation of Medicine in LMICs (sub-Saharan Africa): Enablers, Barriers, and Funding Strategies for Sustainable Health Systems. Frontiers in Public Health.;14:1710904. https://doi.org/10.3389/fpubh.2026.1710904